Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05839535 · ClinicalTrials.gov registry record · Phase 2

Enhancing Modulation Effects of Baduanjin Through Neuromodulation for Knee OA

A Phase 2 study of Knee Osteoarthritis, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
Phase 2
Development phase
140
Enrollment target
1
Study location

NCT05839535 is a Phase 2 study of Knee Osteoarthritis that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 140 participants, below the 303-participant average among 101 other Knee Osteoarthritis trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05839535, a Phase 2 study of Knee Osteoarthritis, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
Phase 2
Development phase
140 participants
Enrollment target
1
Study location

Study Summary

This study will combine brain imaging and neuromodulation tools to investigate the underlying neurobiological mechanisms of exercises. The findings will enhance our understanding of the mechanisms underlying mind-body exercise and facilitate the development of new pain management approaches.

Conditions Studied

Interventions

  • DEVICE sham tDCS
  • DEVICE tDCS
  • BEHAVIORAL BDJ
  • OTHER exercise

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Charlestown

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 2024-03-05
Est. Completion 2028-08-31
Phase Phase 2

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT05839535

The ClinicalTrials.gov registry entry for NCT05839535 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 303-participant average among 101 other Knee Osteoarthritis trials with a reported enrollment target (54% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Knee Osteoarthritis appearing as the primary indexed condition, and to 4 interventions - of which sham tDCS is the first listed.

NCT05839535 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05839535 about?

NCT05839535 is a clinical study titled "Enhancing Modulation Effects of Baduanjin Through Neuromodulation for Knee OA". This study will combine brain imaging and neuromodulation tools to investigate the underlying neurobiological mechanisms of exercises. The findings will enhance our understanding of the mechanisms underlying mind-body exercise and facilitate the development of new pain management approaches.

What is the current status of trial NCT05839535?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2024-03-05. Estimated completion is 2028-08-31.

What conditions does trial NCT05839535 study?

This clinical trial studies the following conditions: Knee Osteoarthritis.

What interventions are being tested in trial NCT05839535?

The interventions under investigation include: sham tDCS (DEVICE), tDCS (DEVICE), BDJ (BEHAVIORAL), exercise (OTHER).

Who is sponsoring clinical trial NCT05839535?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05839535 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Knee Osteoarthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.